Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALVNYSE:CSNASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVAutoliv$101.42-0.7%$89.56$75.49▼$129.38$7.84B1.36818,809 shs441,102 shsCSCredit Suisse Group$0.89$0.89$0.82▼$6.36$2.77B1.2737.84 million shsN/ATLXTelix Pharmaceuticals Limited American Depositary Shares$16.40-1.9%$17.02$13.61▼$30.36$5.54BN/A27,312 shs9,162 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVAutoliv-0.60%+8.21%+22.65%+6.63%-16.86%CSCredit Suisse Group0.00%0.00%0.00%0.00%0.00%TLXTelix Pharmaceuticals Limited American Depositary Shares-1.86%-7.61%-2.61%-5.15%+1,639,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVAutoliv4.6846 of 5 stars3.43.02.50.03.92.53.8CSCredit Suisse GroupN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVAutoliv 2.79Moderate Buy$112.7911.21% UpsideCSCredit Suisse Group 0.00N/AN/AN/ATLXTelix Pharmaceuticals Limited American Depositary Shares 3.00Buy$22.0034.15% UpsideCurrent Analyst Ratings BreakdownLatest TLX, ALV, CS, and MUV2 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ALVAutolivBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/9/2025ALVAutolivBNP Paribas ExaneSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$123.004/21/2025ALVAutolivBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$97.00 ➝ $105.004/17/2025ALVAutolivWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$84.00 ➝ $82.004/15/2025ALVAutolivBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$110.00 ➝ $97.004/15/2025ALVAutolivRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$105.00 ➝ $90.004/10/2025ALVAutolivMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$112.00 ➝ $95.003/12/2025TLXTelix Pharmaceuticals Limited American Depositary SharesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/7/2025ALVAutolivTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$116.003/6/2025ALVAutolivCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVAutoliv$10.35B0.76$14.13 per share7.18$29.40 per share3.45CSCredit Suisse Group$22.88B0.12$0.25 per share3.51$15.26 per share0.06TLXTelix Pharmaceuticals Limited American Depositary Shares$783.21M7.08N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVAutoliv$647M$8.6912.579.360.736.21%28.62%8.24%7/18/2025 (Estimated)CSCredit Suisse Group-$7.64B$0.651.37∞N/A15.12%23.83%1.81%N/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/A0.0034.17N/AN/AN/AN/AN/ALatest TLX, ALV, CS, and MUV2 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/16/2025Q1 2025ALVAutoliv$1.72$2.15+$0.43$2.14$2.50 billion$2.58 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVAutoliv$2.802.76%+13.38%32.22%1 YearsCSCredit Suisse Group$0.055.62%N/A7.69%N/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/ALatest TLX, ALV, CS, and MUV2 DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/8/2025ALVAutolivquarterly$0.702.9%5/21/20255/21/20256/10/20252/21/2025ALVAutolivQuarterly$0.702.87%3/7/20253/7/20253/24/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVAutoliv0.670.960.71CSCredit Suisse Group2.791.531.53TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVAutoliv69.57%CSCredit Suisse Group11.20%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AInsider OwnershipCompanyInsider OwnershipALVAutoliv0.20%CSCredit Suisse GroupN/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVAutoliv69,10077.31 million77.53 millionOptionableCSCredit Suisse Group50,4803.11 billionN/AOptionableTLXTelix Pharmaceuticals Limited American Depositary SharesN/A337.88 millionN/AN/ATLX, ALV, CS, and MUV2 HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Here's WhyMay 14 at 2:47 PM | marketbeat.comTelix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging EfficacyMay 7, 2025 | globenewswire.comShareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLXMay 7, 2025 | accessnewswire.comATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your RightsMay 6, 2025 | accessnewswire.comTelix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)May 5, 2025 | accessnewswire.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Still a Buy?May 5, 2025 | marketbeat.comTelix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)May 2, 2025 | accessnewswire.comTelix Pharmaceuticals Limited American Depositary Shares (TLX)May 1, 2025 | nasdaq.comTLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing InvestigationMay 1, 2025 | accessnewswire.comWhat is William Blair's Estimate for TLX FY2026 Earnings?May 1, 2025 | marketbeat.comTelix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - What's Next?April 30, 2025 | marketbeat.comTLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals LimitedApril 30, 2025 | accessnewswire.comTelix's Illuccix PSMA-PET Imaging Agent Approved in FranceApril 28, 2025 | globenewswire.comLevi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by FraudApril 28, 2025 | accessnewswire.comTelix shares crash 8% on US FDA blowApril 27, 2025 | msn.comTelix Pharmaceuticals Ltd. ADRApril 23, 2025 | wsj.comTelix Reports US$186M Q1 Revenue, Up 62% YOYApril 22, 2025 | globenewswire.comIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy CandidateApril 15, 2025 | globenewswire.comAll You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to BuyApril 14, 2025 | zacks.comTelix Shares May Gain on the Distribution Deal With Cardinal HealthApril 9, 2025 | zacks.comTelix Announces Cardinal Health for Gozellix Commercial DistributionApril 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsTariff Exemptions Set the Stage for a Taiwan Semiconductor RallyBy Gabriel Osorio-Mazilli | April 17, 2025View Tariff Exemptions Set the Stage for a Taiwan Semiconductor RallyTariff-Resilient Tech Stocks: CyberArk & Verisign’s Durable EdgeBy Leo Miller | April 25, 2025View Tariff-Resilient Tech Stocks: CyberArk & Verisign’s Durable EdgeViking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportThe Top 3 Stock Picks at the World’s Greatest Hedge FundBy Leo Miller | May 2, 2025View The Top 3 Stock Picks at the World’s Greatest Hedge FundTLX, ALV, CS, and MUV2 Company DescriptionsAutoliv NYSE:ALV$101.42 -0.69 (-0.68%) As of 05/14/2025 03:47 PM EasternAutoliv, Inc., through its subsidiaries, develops, manufactures, and supplies passive safety systems to the automotive industry in Europe, the Americas, China, Japan, and rest of Asia. It offers passive safety systems, including modules and components for frontal-impact airbag protection systems, side-impact airbag protection systems, seatbelts, steering wheels, and inflator technologies. The company also provides mobility safety solutions, such as pedestrian protection, battery cut-off switches, connected safety services, and safety solutions for riders of powered two wheelers. It primarily serves car manufacturers. Autoliv, Inc. was founded in 1953 and is headquartered in Stockholm, Sweden.Credit Suisse Group NYSE:CS$0.89 0.00 (0.00%) As of 06/13/2023Credit Suisse Group AG is a holding company, which engages in the provision of financial services. It operates through the following four divisions: Wealth Management, Investment Bank, Swiss Bank and Asset Management and four geographic regions: Switzerland, Europe, the Middle East and Africa (EMEA), Asia Pacific, and Americas. The Wealth Management division offers comprehensive wealth management and investment solutions, tailored financing, and advisory services to ultra-high-net-worth (UHNW) and high net-worth (HNW) individuals and external asset managers. The Investment Bank division offers a broad range of financial products and services focused on client-driven businesses and also supports Credit Suisse's Wealth Management division and its clients. The Swiss Bank division offers comprehensive advice and a wide range of financial solutions to private, corporate, and institutional clients in Switzerland. The Asset Management division offers investment solutions and services globally to a broad range of clients, including pension funds, governments, foundations and endowments, corporations, and individuals. The company was founded by Alfred Escher on July 5, 1856 and is headquaTelix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX$16.40 -0.31 (-1.86%) As of 05/14/2025 04:00 PM EasternTelix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
